

Preclinical Development of a UniStac[®]-based Long-acting Tetra-specific Drug for NASH

Onegene Biotechnology



METABOLIC	Preclinical
Product Type	Biological-Protein Product [Multi-specific drug]
Indication	1st indication: NASH, Cirrhosis 2nd indication: Idiopathic Pulmonary Fibrosis
Target	Glucagon-like peptide-1 [GLP-1], Glucagon [GCG], Fibroblast growth factor21 [FGF21], and Interleukin-1 receptor antagonist [IL-1RA]
MoA(Mechanism of Action)	<p> GLP-1 / GCG <ul style="list-style-type: none"> Liver-targeting Cleatosis resolution Metabolic improvement </p> <p> IL-1RA <ul style="list-style-type: none"> Inflammatory control </p> <p> Albumin </p> <p> FGF21 <ul style="list-style-type: none"> Fibrosis improvement NASH resolution </p> <p> <small>MSD AstraZeneca Boehringer Ingelheim atImmune akero 89bio</small> </p>
Competitiveness	<ul style="list-style-type: none"> Best-in-Class Efficacy: Improved efficacy and therapeutic window for the NASH and liver fibrosis resolution compared to the leading FGF21 asset Potential Accelerated Approval: High unmet need in reversing cirrhosis (F4) Potential Multi-Organ Anti-Fibrosis Treatment: Strong anti-fibrosis effect in IPF mouse model
Development Stage	Preclinical
Route of Administration	Subcutaneous Administration